Abstract
FGFR2 fusions/rearrangements (FGFR2fus) occur in ∼15% of patients (pts) with intrahepatic cholangiocarcinoma (iCCA), a disease with poor outcomes upon progression after 1L standard treatment. Derazantinib is a potent FGFR1-3 kinase inhibitor that has shown broad clinical activity in iCCA pts with FGFR2 fusions, mutations and amplifications. Here, we present efficacy and safety data for the completed FGFR2fus+ cohort from study FIDES-01.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
